Cancer dealmaking expanded in Q2 2026, but the money concentrated in a few large deals. Partnerships and M&A gained value as their median deal sizes fell, with scale over breadth. Venture cooled in count and capital, though the average round held. IPOs raised more from fewer, larger listings.
R&D partnerships closed 51 deals worth $41.8B with $2.9B upfront, as the median upfront sank to $20M from $63M. Hengrui Pharma and BMS, up to $950M near-term plus up to $14.3B in option fees and milestones across cancer, hematology, and immunology, and Innovent Biologics and Pfizer, $650M upfront and up to $9.9B for ADCs and multispecifics, defined it.
M&A ran busier and far bigger, 30 deals worth $48.6B including contingents, more than double Q1, though the median fell to $450M from $2.0B. Merck’s $11.3B buy of Bio-Techne in life sciences tools and GSK’s roughly $10.6B purchase of Nuvalent in ROS1 and ALK lung cancer anchored it.
Venture eased to 58 rounds and $2.9B, from 74 and $3.4B, with the average round steady near $50M, fewer deals, not smaller ones. CellCentric’s $220M series D for oral p300/CBP inhibitor inobrodib in multiple myeloma and Sidewinder’s $137M series B in bispecific ADCs led.
IPOs raised more from fewer listings, 3 debuts and $1.1B against 4 and $875M, averaging roughly $383M. Parabilis Medicines’ $771M debut in beta-catenin cancers and METiS TechBio’s roughly $269M Hong Kong listing in AI drug delivery led.
Cancer R&D Partnerships
Cancer-focused R&D partnerships gained momentum in Q2 2026. The quarter produced 51 deals with a combined potential value of $41.8B, up sharply from $30.8B across 55 deals in Q1. Volume eased slightly, yet both headline value and upfront funding moved higher. Total upfront cash and equity climbed to $2.9B from $2.0B, while the average upfront payment rose to $159M from $125M. The median upfront, however, dropped to $20M from $63M, indicating that a handful of large transactions drove the gains rather than broad-based scaling. Across H1 of 2026, the market recorded 106 deals worth $72.6B in total potential value, including $4.9B in upfront cash and equity.
Prominent Cancer R&D Partnerships in Q2 2026
Hengrui Pharma development and commercialization deal with Bristol Myers Squibb – May 2026
Hengrui and BMS formed an early-stage discovery pact across cancer, hematology, and immunology, spanning 13 programs: 4 cancer and hematology assets from Hengrui, 4 immunology assets from BMS on Hengrui’s platforms, and 5 joint programs that Hengrui may co-develop worldwide. BMS took exclusive rights outside China, Hong Kong, and Macau; Hengrui kept those markets. Hengrui leads through proof-of-concept; BMS thereafter. Terms reach up to $950M near-term: $600M upfront, $175M on the first anniversary, and a contingent $175M in 2028, plus up to $14.3B in option fees and milestones and tiered ex-China royalties.
Innovent Biologics development and commercialization deal with Pfizer – May 2026
Innovent and Pfizer formed an early-stage cancer partnership in ADCs and multispecific antibodies, spanning 12 programs: 8 Innovent-originated and 4 Pfizer discovery-stage. Innovent leads discovery through Phase 1; Pfizer runs global late-stage development and commercialization. Rights split into three tiers of 4: Pfizer takes worldwide rights and full costs on the first; rights outside Greater China and most costs on the second; and co-development, US and Europe co-commercialization, and profit-sharing on the third, with Innovent keeping Greater China. Innovent receives $650M upfront and up to $9.9B in milestones (breakout not disclosed), plus up to double-digit royalties.
Â
Cancer M&A
Cancer-focused M&A accelerated sharply in Q2 2026. The quarter delivered 30 deals worth $48.6B in total value, including contingents, more than double the $23.7B across 21 deals in Q1. Cash consideration excluding contingents also rose steeply, to $38.6B from $20.3B. Deal economics per transaction, however, softened. The average upfront value slipped to $1.8B from $2.9B, and the median fell substantially to $450M from $2.0B. The split points to a quarter defined by higher deal volume and generally smaller individual transactions, with a few large acquisitions lifting the aggregate. Across H1 of 2026, cancer M&A reached 51 deals worth $72.3B, including contingents and $58.9B in cash, excluding contingents.
Prominent Cancer M&A in Q2 2026
Merck acquiring Bio-Techne – June 2026
Merck is acquiring Bio-Techne, a life sciences supplier of research reagents, instruments, and diagnostics across its R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics brands, deepening Merck’s position in multi-omics, spatial biology, and precision diagnostics. Shareholders receive $73 per share in cash, a 24% premium to the prior one-day close and 36% to the one-month VWAP, for an $11.3B enterprise value. Funded through cash and new debt, the deal is expected to be earnings-accretive with roughly EUR 140 million in annual cost synergies by year three, closing in late 2026 or early 2027.
GSK acquired Nuvalent – June 2026
GSK has acquired Nuvalent to build a lung cancer franchise. Nuvalent brings two registration-stage assets: Zidesamtinib (NVL-520), a ROS1 inhibitor, and Neladalkib (NVL-655), an ALK inhibitor for ALK-positive NSCLC, plus Phase 1 HER2-targeted NVL-330 and preclinical programs. Shareholders receive $124 per share in cash, a 40% premium to the prior one-day close and 26% to the 30-day VWAP, for roughly $10.6B in equity value. GSK expects revenue from 2027, with both leads seen as potential blockbusters. Announced in June with an expected Q3 2026 close, the deal completed on July 15, 2026.
Cancer Venture Funding
Cancer-focused venture funding cooled in Q2 2026. The quarter recorded 58 financing rounds raising $2.9B, down from 74 rounds and $3.4B in Q1. Both deal activity and total capital raised eased. Average funding per round, however, held steady at roughly $50M, against about $46M in Q1. The read points to fewer deals rather than smaller ones. Across H1 of 2026, Cancer companies completed 132 venture rounds and raised a combined $6.3B.
Prominent Cancer Venture Funding in Q2 2026
CellCentric Series D $220M – May 2026
CellCentric closed an oversubscribed $220M series D, led by Venrock Healthcare Capital Partners, to fund pivotal development of inobrodib in multiple myeloma. New backers Fidelity, Sofinnova Partners, and HBM Healthcare joined existing investors RA Capital, Forbion, Pfizer, Avego BioScience Capital, and American Cancer Society BrightEdge. Inobrodib is a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma, tested in over 500 patients. December 2025 ASH data showed 20 mg inobrodib plus pomalidomide and dexamethasone (InoPd) at least doubled response rates in heavily pretreated patients (median five prior lines). Holding FDA Fast Track and orphan drug status for RRMM, proceeds will continue Phase 2 DOMMINO-1, launch global Phase 3 DOMMINO-2 in H2 2026, and expand into combination and maintenance settings.
Sidewinder Series B $137M – April 2026
Sidewinder Therapeutics raised an oversubscribed $137M series B, co-led by Frazier Life Sciences and Novartis Venture Fund, to advance precision bispecific ADCs toward the clinic. Sole series A investor OrbiMed joined new backers Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management, and Alexandria Venture Investments. Sidewinder’s bispecific ADCs target receptor co-complexes on solid tumors, pairing an oncogenic driver receptor with an internalizing receptor to sharpen specificity and payload delivery. Lead indications span squamous cell carcinomas of the lung and head and neck, plus gastrointestinal cancers such as colorectal. Partnered with Lonza on Synaffix’s site-specific linker-payload platform and founded in 2023 with OrbiMed, the San Diego company has now raised $162M in total, with its lead ADC set to enter the clinic in 2027.
Cancer IPO Activity
Cancer-focused IPO activity raised more capital in Q2 2026 despite fewer listings. The quarter delivered 3 IPOs generating $1.1B, against 4 IPOs raising $875M in Q1. Volume dipped, yet proceeds rose, pointing to larger deal sizes. Q2 listings raised roughly $383M each on average, versus about $219M in Q1. Across H1 of 2026, Cancer companies completed 7 IPOs and raised a combined $2.0B.
Prominent Cancer IPO Activity in Q2 2026
Parabilis Medicines IPO $770.5M – May 2026
Parabilis Medicines closed an upsized Nasdaq IPO of 38,525,000 shares at $20.00, including the fully exercised 5,025,000-share greenshoe, for $771M gross. A concurrent Regeneron placement added roughly $75M, 4,166,666 shares at $18.00 (90% of the IPO price), tied to an Antibody-Helicon Conjugates collaboration. All preferred, and a $50M SAFE held by Explore Investments LLC converted at close, lifting Parabilis’s 2026 haul above $1.2B across financings and collaborations. Parabilis develops Helicons, stabilized helical peptides aimed at historically undruggable targets, led by zolucatetide (formerly FOG-001), advancing toward a planned Phase 3 registrational trial in desmoid tumors in Wnt and beta-catenin-driven cancers. Leerink Partners, BofA Securities, Evercore ISI, and Guggenheim Securities ran the books, with LifeSci Capital as passive bookrunner. Shares opened on the Nasdaq Global Select Market as PBLS on June 10, 2026, closing June 11.
METiS IPO $269.6M – May 2026
METiS TechBio priced its Hong Kong IPO at HK$10.50 per H Share, selling 201,229,000 H Shares before the over-allotment for HK$2,113M gross and HK$1,993M net after HK$120M in expenses, implying a HK$12,101M market cap. The raise, roughly US$269M, was Hong Kong’s largest healthcare IPO of 2026 to date. The split ran 160,983,000 shares (80%) international and 40,246,000 (20%) Hong Kong public after clawback, with 30,184,000 over-allocated. Retail demand hit 6,910.96 times, and the international tranche 33.86 times. Eighteen cornerstones took 110,415,000 shares (54.87%), led by BlackRock at 37,304,500 (18.54%), with UBS AM Singapore, Mirae, HHLRA, Deerfield, and RTW Funds. METiS is a Beijing-based AI drug delivery and nanomaterial company with a pipeline across cancer, immunology, CNS, and metabolic disease. Lead asset MTS-004, an AI-designed oral formulation for pseudobulbar affect, cleared Phase 3 in China, with an NMPA NDA expected in 2026. Shares opened under code 7666 on May 13, 2026.
Also check out Antibody (Including ADC and DAC) R&D Partnerships, M&A, Ventures & IPOs – H1 2026
